ISRCTN13102817已完成Unknown
Early Access experience with burosumab in adults with X-linked hypophosphataemia in the UK: real-world clinical and patient-reported outcomes
Kyowa Kirin International (United Kingdom)0 个研究点目标入组 142 人开始时间: 2023年8月1日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 142
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 性别
- All
入选标准
- •All participants enrolled in the burosumab early access programme (EAP) will be considered for inclusion
排除标准
- •Participants opting out will not have their clinical data collected
研究者
相似试验
已完成
3 期
Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)X-linked HypophosphatemiaNCT02526160Kyowa Kirin, Inc.134
进行中（未招募）
1 期
A sing le-arm, phase I study of ramucirumab in combination with erlotinib or osimertinib in previously untreated patients with EGFR mutantion-posit ive metastatic Non-small cell lung cancer with brain metastaseslung carcinoma, non small cellD002289JPRN-jRCT2051190027Kaneda Hiroyasu6
招募中
Unknown
Efficacy of brolucizumab for age-related macular degeneratioJPRN-UMIN000050137Kawasaki Medical School100
招募中
2 期
Phase II study of ramucirumab for the patients with advanced hepatocellular carcinoma previously treated with lenvatinibHepatocellular carcinomaJPRN-jRCT1041190083Yamashita Tatsuya33
已完成
1 期
BUBBLE: Buparlisib with bortezomib in relapsed or refractory multiple myelomaTopic: CancerSubtopic: Haematological OncologyDisease: MyelomaCancerISRCTN22287432niversity of Birmingham (UK)60